Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (September 2013)
14 slides from Somnomed's investor presentation, Sep 25, 2013
Slide 1: Building a Global Medical Device Business – Investor Briefing
For personal use only BUILDING A GLOBAL MEDICAL DEVICE BUSINESS Financial Year 2012 – 13 Investor Briefing Sydney – Melbourne – Brisbane 25 September – 1 October, 2013 COAT ™ Continuous Open Airway Therapy
Slide 2: Disclaimer & Regulatory Disclosure
For personal use only Disclaimer & Regulatory Disclosure This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s
Slide 3: Main achievements in 2012/13
SomnoMed: Global Building and expanding the foundations of a global medical device business For personal use only Main achievements in 2012/13 • Expansion of geographic coverage and achievement of full integration in Europe through acquisitions in France, Sweden and Germany (1.7.13) • Introduction o
Slide 4: Continuous growth in all regions and departments in 2012/13
SomnoMed: Global Continuous growth in all regions and departments in 2012/13 For personal use only 1 2 3 4 SomnoDent® Units sold Revenues reached $18.5 Operating Profits before EBITDA $830k after totaled 35,841 million corporate overheads, investing $1.5m in research and medical and acquisition deve
Slide 5: Europe Accelerating Fast
SomnoMed: Global Europe Accelerating Fast For personal use only % Unit Sales Contribution By Region SomnoMed operating in: 100% Europe: 16% Sweden, Norway, Denmark 25% 27% 31% Holland, Belgium, Luxembourg 80% France 16% Germany, Switzerland, Austria 12% 12% Italy 60% 12% Spain United Kingdom APAC: 4
Slide 6: Finance: Strong revenue growth and maintenance of base profitability
SomnoMed: Finance Strong revenue growth and maintenance of base profitability For personal use only Financial Summary ($000's) 08/09 09/10 10/11 11/12 12/13 Revenue 7,737 10,714 12,335 15,246 18,489 Gross Margin 4,059 6,084 8,176 10,357 12,267 Group Gross Margin % 52.5% 56.8% 66.3% 67.9% 66.3% MAS G
Slide 7: Profits maintained despite significant extraordinary expenses/investments
SomnoMed: Finance Profits maintained despite significant extraordinary expenses/ investments in acquisitions and building medical capabilities For personal use only Financial Summary ($000's) FY 12/13 Underlying EBITDA Total Year 1st Half 2nd Half Revenues 18,498 9,026 9,472 Posted EBITDA 830 723 10
Slide 8: Positive cash generated resulted in freeing up capital
SomnoMed: Finance Positive cash generated resulted in freeing up capital For personal use only CONSOLIDATED CASH FLOW 2012 2013 SomnoMed Limited ($000's) Cash from OPERATING ACTIVITIES 290 572 Payments for fixed assets (270) (171) Acquisitions (300) (522) Payment for intangibles (212) (100) INVESTIN
Slide 9: North America: Restructuring of laboratory and dental sales operations
SomnoMed: North America Restructuring of laboratory and dental sales operations to strengthen base US business For personal use only • CHANGES IN MANAGEMENT AND PROCESSES OF US LAB OPERATION TO IMPROVE CUSTOMER SERVICE Improving service delivery, product turn around times and communication with cust
Slide 10: North America: Building a managed care department
SomnoMed: North America Building a managed care department – developing relationships with health care providers – opening communication with insurers & payers For personal use only • Billing department offers dental practitioners medical reimbursement services – growing number of dental accounts •
Slide 11: North America: Building medical credentials and capabilities
SomnoMed: North America Building medical credentials and capabilities in 2012/13 to accelerate future business For personal use only • Adding medical experience to SomnoMed – North America executive team: • Appointment of SomnoMed North America medical device executives – President, VP Marketing & S
Slide 12: 2013/14 – Ongoing expansion benefitting from investments made
SomnoMed: Global 2013/14 – Ongoing expansion benefitting from investments made in 2012/13 For personal use only 1. GLOBAL UNITS SALES >43,000 (+20%) GLOBAL REVENUES >$22 MILLION Units Revenues 44000 23000 42000 22000 21000 40000 20000 38000 19000 36000 18000 34000 17000 16000 32000 2012/13 2013/14 2
Slide 13: 2013/14 – Ongoing expansion benefitting from investments made
SomnoMed: Global 2013/14 – Ongoing expansion benefitting from investments made in 2012/13 For personal use only 3. INTEGRATING MARKETS INTO SOMNOMED GLOBAL OPERATION • Republic of Korea • Italy 4. EXPANDING INTO NEW MARKETS • Russia • Finland 5. STRENGTHENING MEDICAL ACTIVITIES - FOCUSING ON MEDICAL
Slide 14: Contact details
For personal use only Contact details EXECUTIVE CHAIRMAN | Dr Peter Neustadt CHIEF FINANCIAL OFFICER | Mr Neil Verdal–Austin Address | Level 3, 20 Clarke Street Crows Nest NSW 2065 Australia Telephone | +61 (2) 9467 0400 Website | www.somnomed.com.au COAT ™ Continuous Open Airway Therapy